The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial

Psychiatric Genetics

Volumn 23, Issue 6, 2013, Pages 225-232

  Nielsen, David A ^a,b   Hamon, Sara C ^c   Kosten, Thomas R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

cocaine; gene; opioid; polymorphism; treatment; vaccine

Indexed keywords

COCAINE; COCAINE VACCINE; DNA; KAPPA OPIATE RECEPTOR; METHADONE; UNCLASSIFIED DRUG; VACCINE;

ADDICTION SEVERITY INDEX; ADULT; ALLELE; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION;

ADULT; COCAINE-RELATED DISORDERS; DEMOGRAPHY; FEMALE; HUMANS; MALE; RECEPTORS, OPIOID, KAPPA; TREATMENT OUTCOME; VACCINES;

EID: 84887090767     PISSN: 09558829     EISSN: 14735873     Source Type: Journal    
DOI: 10.1097/YPG.0000000000000008     Document Type: Article

References (50)

1. APA (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association.
2. Carroll KM (1997). Manual-guided psychosocial treatment. A new virtual requirement for pharmacotherapy trials? Arch Gen Psychiatry 54: 923-928.
3. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ (2004). Efficacy of disulfiram and cognitive behavior therapy in cocainedependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 61: 264-272.
4. Chefer VI, Czyzyk T, Bolan EA, Moron J, Pintar JE, Shippenberg TS (2005). Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25: 5029-5037.
5. Claye LH, Maisonneuve IM, Yu J, Ho A, Kreek MJ (1997). Local perfusion of dynorphin A 1-17 reduces extracellular dopamine levels in the nucleus accumbens. NIDA Res Monogr 174: 113.
6. De Wit H (1996). Priming effects with drugs and other reinforcers. Exp Clin Psychopharm 4: 5-10.
7. DeLeon J, Armstrong SC, Cozza KL (2006). Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 and CYP450 2C19. Psychosomatics 47: 75-85.
8. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW (2008). A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165: 179-187.
9. Dykstra LA, Preston KL, Bigelow GE (1997). Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology (Berl) 130: 14-27.
10. Edenberg HJ, Wang J, Tian H, Pochareddy S, Xuei X, Wetherill L, et al. (2008). A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. Hum Mol Genet 17: 1783-1789.
11. Gerra G, Leonardi C, Cortese E, D'Amore A, Lucchini A, Strepparola G, et al. (2007). Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction. Am J Med Genet B Neuropsychiatr Genet 144: 771-775.
12. Goldman D, Oroszi G, Ducci F (2005). The genetics of addictions: uncovering the genes. Nat Rev Genet 6: 521-532.
13. Haile CN, Kosten TA, Kosten TR (2008). Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 34: 355-381.
14. Haile CN, Kosten TR, Kosten TA (2009). Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse 35: 161-177.
15. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW (2010). Cocainespecific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 67: 59-65.
16. Heidbreder CA, Shippenberg TS (1994). U-69593 prevents cocaine sensitization by normalizing basal accumbens dopamine. Neuroreport 5: 1797-1800.
17. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, et al. (2002). Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20: 1196-1204.
18. Kosten TR,Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, Nielsen DA (2012). Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry 73: 219-224.
19. Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A (1999). Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther 288: 260-269.
20. Kumar D, Chakraborty J, Das S (2012). Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. Prog Neuropsychopharmacol Biol Psychiatry 36: 225-230.
21. Laje G, McMahon FJ (2007). The pharmacogenetics of major depression: past, present, and future. Biol Psychiatry 62: 1205-1207.
22. Leshner AI (1997). Addiction is a brain disease, and it matters. Science 278: 45-47.
23. Levran O, Londono D, O'Hara K, Nielsen DA, Peles E, Rotrosen J, et al. (2008). Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav 7: 720-729.
24. Malhotra AK, Murphy GM Jr, Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161: 780-796.
25. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (2005). Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58: 158-164.
26. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR (2009). Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 66: 1116-1123.
27. McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674-5683.
28. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. (1992). The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 9: 199-213.
29. McLellan AT, Lewis DC, O'Brien CP, Kleber HD (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284: 1689-1695.
30. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160: 1830-1835.
31. R Development Core Team (2009). R: a language and environment for statistical computing 2.9.1. Vienna, Austria: R Foundation for Statistical Computing.
32. Rogers JF, Nafziger AN, Bertino JSJ (2002). Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 113: 746-750.
33. SAMSHA (2011). Results from the 2010 National Survey on Drug Use and Health (NSDUH). NSDUH Series H-41.
34. Rockville, MD: Substance Abuse and Mental Health Services Administration.
35. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J,Weiller E, Bonara LI, et al. (1997). Reliability and validity of the MINI International Neuropsychiatric Interview (M.I.N.I.): according to the SCID-P. Eur Psychiatry 12: 232-241.
36. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, et al. (1998). Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17: 886-897.
37. Simpson DD, Joe GW, Broome KM (2002). A national 5-year follow-up of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 59: 538-565.
38. Sofuoglu M, Kosten TR (2006). Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Investig Drugs 11: 91-98.
39. Spanagel R, Herz A, Shippenberg TS (1990). The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55: 1734-1740.
40. Uhl GR, Hall FS, Sora I (2002). Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 7: 21-26.
41. Unterwald EM, Rubenfeld JM, Kreek MJ (1994). Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 5: 1613-1616.
42. Unterwald EM, Kreek MJ, Cuntapay M (2001). The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain Res 900: 103-109.
43. Walsh SL, Geter-Douglas B, Strain EC, Bigelow GE (2001a). Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther 299: 147-158.
44. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001b). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157: 151-162.
45. Weisner C, Matzger H, Kaskutas LA (2003). How important is treatment? Oneyear outcomes of treated and untreated alcohol-dependent individuals. Addiction 98: 901-911.
46. Xuei X, Dick D, Flury-Wetherill L, Tian HJ, Agrawal A, Bierut L, et al. (2006). Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry 11: 1016-1024.
47. Yuferov V, Fussell D, LaForge KS, Nielsen DA, Gordon D, Ho A, et al. (2004). Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 14: 793-804.
48. Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J (2008). The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry 13: 531-543.
49. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2004a). Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) 172: 422-429.
50. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2004b). Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) 173: 146-152.